Drug intelligence / Profile preview

fentanyl + midazolam

Development stage
Unknown
Lead developer
Janssen Pharmaceutica
Modality
Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Intravenous, Intramuscular, Intranasal, Oral, Buccal
01

Overview

Fentanyl + midazolam is a combination of two pharmaceutical drugs commonly used for procedural sedation and analgesia, particularly in emergency and perioperative settings. Fentanyl is a potent synthetic opioid analgesic that acts primarily as an agonist at the mu-opioid receptor, providing rapid and effective pain relief. Midazolam is a short-acting benzodiazepine that enhances the effect of the neurotransmitter GABA at the GABA(A) receptor, resulting in sedation, anxiolysis, amnesia, and muscle relaxation. When used together intravenously or via other routes under medical supervision, this combination provides synergistic effects for conscious sedation—offering both pain control (from fentanyl) and anxiolysis/amnesia (from midazolam). This allows for lower doses of each drug compared to monotherapy while improving patient comfort during procedures such as endoscopy or orthopedic reductions. The primary risks include respiratory depression due to additive central nervous system depressant effects; therefore, use requires close monitoring by trained personnel with resuscitation equipment available[1][2][3][5][6][7].

Other names
midazolam and fentanylmidazolam plus fentanylmidazolam/fentanyl
02

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on fentanyl + midazolam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on fentanyl + midazolam.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call